US1598641074
© BusinessWire
11.12.2025
CRL
LISTED
NYSE
Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Launched in December 2024, with the inaugural cohort announced in April 2025, the program provides early-stage biotechnology pioneers with access to extensive scientific and commercial expertise, as w...
Themefolio
Profiler
Peergroup
© BusinessWire
01.12.2025
CRL
LISTED
NYSE
Charles River Laboratories to Present at Evercore Healthcare Conference
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Evercore 8th Annual Healthcare Conference on Wednesday, December 3rd, at 10:00 a.m. ET. Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends.
A live webcast of the presentation will be...
Themefolio
Profiler
Peergroup
© BusinessWire
24.11.2025
CRL
LISTED
NYSE
Charles River Laboratories Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL
News Preview
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Charles River Laboratories International, Inc. (“Charles River” or the “Company”) (NYSE: CRL).
In February 2023, the Company disclosed that it had received a subp...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
17.11.2025
CRL
LISTED
NYSE
Charles River Laboratories to Present at Jefferies Global Healthcare Conference
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18th, at 11:30 a.m. GMT (6:30 a.m. ET). Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends.
A live webcast of th...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
05.11.2025
CRL
LISTED
NYSE
Charles River Laboratories Provides Update on Strategic Review
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today announced an update on its Board of Directors’ comprehensive strategic review of the Company’s business and growth prospects. The Board strongly supports the Company’s strategic direction and believes it should continue to focus on strengthening its leading scientific portfolio withi...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
CRL
LISTED
NYSE
Charles River Laboratories Announces Third-Quarter 2025 Results
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2025. For the quarter, revenue was $1.00 billion, a decrease of 0.5% from $1.01 billion in the third quarter of 2024.
The impact of foreign currency translation increased reported revenue by 1.3%, and the divestiture of a small Safety As...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
CRL
LISTED
NYSE
Charles River Laboratories Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL
News Preview
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Charles River Laboratories International, Inc. (“Charles River” or the “Company”) (NYSE: CRL).
In February 2023, the Company disclosed that it had received a sub...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
CRL
LISTED
NYSE
Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to shareholders.
If you currently own Charles River stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the r...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2025
CRL
LISTED
NYSE
Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) and The Francis Crick Institute (Crick) today announced a new collaboration around Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies.
This agreement leverages an int...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
CRL
LISTED
NYSE
Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities
News Preview
Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic collaboration with X-Chem, Inc., the pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit identification (Hit ID) capabilities and accelerate the discovery of novel therapeutics. This partnership enables Cha...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
CRL
LISTED
NYSE
Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the creation of a global, cross-functional Scientific Advisory Board, led by Dr. Namandjé N. Bumpus, to guide the Company’s strategic focus on New Approach Methodologies (NAMs). NAMs are non-clinical tools that enhance the predictability of efficacy and safety in the develo...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
CRL
LISTED
NYSE
Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2025 financial results on Wednesday, November 5th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 5th, at 9:00 a.m. ET.
Investors will have the opportunity to listen to a live webcast of the conf...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
08.10.2025
CRL
LISTED
NYSE
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) and Toxys today announced a collaboration that offers Charles River’s clients access to ReproTracker®, a state-of-the-art human stem cell-based in vitro assay that rapidly and reliably identifies developmental toxicity hazards of new drugs and chemicals.
This press release features multim...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2025
CRL
LISTED
NYSE
Charles River Laboratories Announces Chief Financial Officer Transition
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Flavia H. Pease, Corporate Executive Vice President and Chief Financial Officer (CFO), has resigned from her role, effective September 29, 2025, to pursue another opportunity. Following Ms. Pease’s departure, Michael G. Knell, Corporate Senior Vice President and Chief...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2025
CRL
LISTED
NYSE
Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) has recently announced two strategic collaborations across its contract development and manufacturing organization (CDMO), aimed at advancing novel oncology research and development. These collaborations include forming an alliance with the Parker Institute for Cancer Immunotherapy and sup...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
CRL
LISTED
NYSE
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:
Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9th, at 10:00 a.m. EDT; and
Baird 2025 Global Healthcare Conference on Wednesday, September 10th, at 9:40 a.m. EDT.
M...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
CRL
LISTED
NYSE
Charles River Enhances Cell Therapy Flex Platform through Collaboration with Akadeum Life Sciences
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) and Akadeum Life Sciences, a leader in advanced cell separation technologies, announced today the integration of Akadeum’s GMP-grade Human T Cell Leukopak Isolation Kit into Charles River’s Cell Therapy Flex Program.
Charles River’s Cell Therapy Flex Platform originated as an off-the-she...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2025
CRL
LISTED
NYSE
Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) has joined the EASYGEN (Easy Workflow Integration for Gene Therapy) Consortium, a European Union (EU)-backed effort to produce CAR-T cell therapies faster, make them more affordable, and increase patient access throughout Europe. The Consortium aims to develop a fully automated, hospital-b...
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
CRL
LISTED
NYSE
Charles River and BioTech Social Inc. Pursue Crowdfunding Partnership
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) and BioTech Social Inc. (BSI) today announced the exploration of a potential client-centric collaboration to enable Charles River Incubator (CIP) and Accelerator (CAP) Program participants to access the BioTech Funding Portal, an investment crowdfunding platform for life science companies....
Themefolio
Profiler
Peergroup
© BusinessWire
22.07.2025
CRL
LISTED
NYSE
Charles River Joins Elly’s Team to Drive Rare Disease Gene Therapy Development
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) and Elly’s Team, a parent-led foundation striving to find a cure for Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS), a rare genetic disorder, have announced a plasmid DNA contract development and manufacturing organization (CDMO) agr...
Themefolio
Profiler
Peergroup
© BusinessWire
15.07.2025
CRL
LISTED
NYSE
Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2025 financial results on Wednesday, August 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 6th, at 9:00 a.m. ET.
Investors will have the opportunity to listen to a live webcast of the confere...
Themefolio
Profiler
Peergroup
© BusinessWire
16.06.2025
CRL
LISTED
NYSE
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a recycling program, developed in partnership with international recycling leader TerraCycle®, to give new life to single-use plastic cartridges. This groundbreaking collaboration offers users of Charles River’s Endosafe® bacterial endotoxin testing (BET) cartridge technolo...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
CRL
LISTED
NYSE
Charles River Laboratories to Present at William Blair and Jefferies Conferences
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 4th, at 10:30 a.m. ET. Management will present an overview of Charles R...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
CRL
LISTED
NYSE
Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington’s Disease Research
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) and CHDI Foundation, Inc., today announced an extension of their ongoing drug discovery partnership into the foreseeable future. The organizations began working together in 2005 to expedite therapeutic development for Huntington’s disease (HD), a genetic neurological disorder that causes t...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
CRL
LISTED
NYSE
Charles River Laboratories to Present at Bank of America Health Care Conference
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Bank of America 2025 Health Care Conference on Wednesday, May 14th, at 8:40 a.m. PT (11:40 a.m. ET). Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends.
A live webcast of the presenta...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
CRL
LISTED
NYSE
Charles River Laboratories Announces First-Quarter 2025 Results
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024.
The impact of foreign currency translation reduced reported revenue by 0.9%. Excluding this impact, revenue decreas...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
CRL
LISTED
NYSE
Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees and a strategic review of the Company’s bus...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
CRL
LISTED
NYSE
Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the initial cohort of its Charles River Incubator Program (CIP). Launched in December 2024, the program offers early-stage biotechnology pioneers access to extensive scientific and commercial expertise and a wide ecosystem of discovery, development, and manufacturing capabi...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
CRL
LISTED
NYSE
Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL), ahead of the American Association for Cancer Research® (AACR) Annual Meeting in Chicago, IL, has announced updates to its comprehensive portfolio of products and services supporting the discovery and development of novel oncology drugs. Based solely on projected population growth, the num...
Themefolio
Profiler
Peergroup
© BusinessWire
15.04.2025
CRL
LISTED
NYSE
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2025 financial results on Wednesday, May 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, May 7th, at 9:00 a.m. ET.
Investors will have the opportunity to listen to a live webcast of the conference call...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
CRL
LISTED
NYSE
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications with significant unmet need. The discovery is the first using Logica®, an artificial intelligence (AI)-powered drug de...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
CRL
LISTED
NYSE
Charles River Laboratories to Present at Barclays Global Healthcare Conference
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, at 9:30 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.
A live webcast of the presentation wil...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
CRL
LISTED
NYSE
Charles River Announces Agreement with Singapore General Hospital
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement with Singapore General Hospital (SGH) to provide Current Good Manufacturing Practice (CGMP) -compliant master cell banking (MCB) and next-generation sequencing (NGS)-based services for use in cell line characterization. SGH will use cord blood to derive and man...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
CRL
LISTED
NYSE
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth quarter and full-year 2024 and provided guidance for 2025. For the quarter, revenue was $1.00 billion, a decrease of 1.1% from $1.01 billion in the fourth quarter of 2023.
The impact of foreign currency translation reduced reported revenue by 0.1%...
Themefolio
Profiler
Peergroup
© BusinessWire
11.02.2025
CRL
LISTED
NYSE
Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) and Deciphex, a leader in AI-powered digital pathology, today announced the next phase of a strategic collaboration to focus on advancing cutting-edge image management solutions, while continuing to develop novel artificial intelligence (AI) tools for toxicologic pathology. Together, Decip...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2025
CRL
LISTED
NYSE
Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2024 financial results and provide 2025 guidance on Wednesday, February 19th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 19th, at 8:30 a.m. ET.
Investors will have the opportun...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
CRL
LISTED
NYSE
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Apollo™ for CRADL®, a secure cloud-based platform that enhances leading vivarium rental services through a digital platform that connects clients effortlessly with the training, tools and services needed to start research quickly. As a digital companion to CRA...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2025
CRL
LISTED
NYSE
Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio (“Akron”), a leading supplier of critical materials and services for advanced therapies, today announced the integration of Akron’s Closed System Solutions (CSS)™ line of liquid cytokines produced under current good manufacturing practices (CGMP) onto Charles River’s Cell The...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
CRL
LISTED
NYSE
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 2:15 p.m. PT (5:15 p.m. ET). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.
A live webcast of the pres...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
CRL
LISTED
NYSE
Charles River Introduces Global Biotech Incubator Program
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Charles River Incubator Program (CIP), specializing in supporting early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies.
“The Charles River Incubator Program launch, through our Global...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
CRL
LISTED
NYSE
Charles River Laboratories to Present at Evercore ISI Investor Conference
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th, at 10:00 a.m. ET. Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends.
A live webcast of the presentation wil...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2024
CRL
LISTED
NYSE
Charles River Laboratories to Present at UBS and Jefferies Conferences
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the UBS Global Healthcare Conference on Tuesday, November 12th, at 10:15 a.m. PT (1:15 p.m. ET), and the Jefferies London Healthcare Conference on Wednesday, November 20th, at 2:00 p.m. GMT (9:00 a.m. ET).
Management will provide an overview of Char...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
CRL
LISTED
NYSE
Charles River Laboratories Announces Third-Quarter 2024 Results
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.6% from $1.03 billion in the third quarter of 2023.
The impact of foreign currency translation benefited reported revenue by 0.4%, and an acquisition contributed 0.9% to c...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2024
CRL
LISTED
NYSE
Charles River Launches New Retrogenix® Non-Human Protein Library
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Retrogenix® Non-Human Protein Library. The non-human protein library helps biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species selection.
“Developed in-house using the innovat...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
CRL
LISTED
NYSE
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 6th, at 9:30 a.m. ET.
Investors will have the opportunity to listen to a live webcast of the confe...
Themefolio
Profiler
Peergroup
© BusinessWire
03.10.2024
CRL
LISTED
NYSE
Charles River Provides Translational Expertise at Neuroscience 2024
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 2024, the annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together leading researche...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2024
CRL
LISTED
NYSE
Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement with H. Lundbeck A/S (Lundbeck) to utilize Logica® to progress critical brain disease research.
“We are excited to partner with Lundbeck as they work toward the discovery of novel treatments for neurodegenerative disease,” said Professor Julie Frearson, Ph.D.,...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2024
CRL
LISTED
NYSE
Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) and CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announced a strategic collaboration within the acceleration program DanubeNeuro, an initiative focused on identifying and advancing pioneering academic research projects with the potential to create new drugs and in...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
CRL
LISTED
NYSE
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
News Preview
Collaboration stands to advance novel therapeutic applications across multiple neurologic conditions
WILMINGTON, Mass., MIAMI and HAIFA, Israel, Sept. 4, 2024 /PRNewswire/ -- Charles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2024
CRL
LISTED
NYSE
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced the launch of a five-year strategic collaboration to provide Charles River’s clients access to a comprehensive global service and technology platform for the applicat...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2024
CRL
LISTED
NYSE
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:
Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5th, at 9:15 a.m. EDT; and
Baird 2024 Global Healthcare Conference on Tuesday, September 10th, at 10:15 a.m. EDT.
Ma...
Themefolio
Profiler
Peergroup
© Newsfile
07.06.2023
CRL
LISTED
NYSE
Charles River Shareholder Action Reminder
News Preview
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Charles River To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - June 6, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Charles River...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
